BerryVin (Vitis vinifera and Vaccinium angustifolium)

BerryVin is a proprietary blend combining Vitis vinifera (grape) and Vaccinium angustifolium (wild blueberry) extracts, delivering polyphenols including resveratrol, oligomeric proanthocyanidins (OPCs), and anthocyanins. These bioactives act as free radical scavengers and upregulate endogenous antioxidant enzymes, theoretically supporting vascular and cellular protection.

Origin & History

BerryVin is a branded blend of grape (Vitis vinifera) and lowbush blueberry (Vaccinium angustifolium) extracts, marketed for antioxidant support. While specific extraction methods and standardization for BerryVin are not documented in available research, similar Vaccinium extracts are typically produced using water-ethanol solvent extraction methods to concentrate polyphenols like proanthocyanidins (PACs), flavonoids, and phenolic acids.

Historical & Cultural Context

No historical or traditional use data exists for BerryVin as a branded blend. While cranberries (related Vaccinium species) are widely used today, the research indicates their UTI applications lack strong traditional roots and represent primarily modern usage post-2000.

Health Benefits

• No direct clinical evidence exists for BerryVin specifically - benefits are theoretical based on component ingredients
• Related Vaccinium species (cranberry) show UTI prevention in women with recurrent infections (RR 0.68, moderate evidence from Cochrane review)
• Cranberry extracts demonstrate 49-59% reduction in antibiotic use for UTIs (moderate-low certainty evidence from network meta-analysis)
• Anti-adhesion effects against E. coli through A-type proanthocyanidins (mechanism studies only)
• Potential antioxidant activity from polyphenols (no clinical trials for BerryVin)

How It Works

Anthocyanins from Vaccinium angustifolium and OPCs from Vitis vinifera neutralize reactive oxygen species (ROS) by donating hydrogen atoms, while resveratrol activates SIRT1 deacetylase and upregulates Nrf2-mediated transcription of antioxidant enzymes including superoxide dismutase (SOD) and catalase. Proanthocyanidins also inhibit NF-κB signaling, reducing downstream expression of pro-inflammatory cytokines such as TNF-α and IL-6. Additionally, grape-derived OPCs inhibit xanthine oxidase, directly reducing superoxide anion production at the enzymatic level.

Scientific Research

No clinical trials, RCTs, or meta-analyses specifically on BerryVin were identified in the research. Related evidence comes from cranberry studies including a Cochrane review of 50 RCTs (n=8857) and a network meta-analysis of 20 RCTs (n=3091), but these investigated different Vaccinium species for UTI prevention, not the BerryVin blend.

Clinical Summary

No randomized controlled trials exist specifically for the BerryVin blend, making direct efficacy claims unsupported by clinical evidence. Component-level data provides context: a Cochrane meta-analysis of cranberry (a related Vaccinium species) found a relative risk reduction of 0.68 for recurrent UTIs in women across trials involving hundreds of participants. Vitis vinifera grape seed extract has been studied in small RCTs (n=20–80) showing reductions in oxidative stress biomarkers such as malondialdehyde (MDA) and improvements in flow-mediated dilation at doses of 150–300 mg daily. Extrapolation from these component studies to BerryVin requires caution, as synergistic or antagonistic interactions between the two extracts have not been formally evaluated.

Nutritional Profile

BerryVin is a proprietary blend combining Vitis vinifera (grape) and Vaccinium angustifolium (lowbush blueberry) extracts; exact standardization ratios are not publicly disclosed, limiting precise concentration data. Based on known constituent profiles: Polyphenols are the dominant bioactive class — Vitis vinifera components contribute oligomeric proanthocyanidins (OPCs) typically at 80-95% purity in standardized grape seed extracts, resveratrol (trans-resveratrol ~50-100 mcg/g in skin extracts), quercetin, kaempferol, and anthocyanins (primarily in grape skin, ~1.5-3 mg cyanidin-3-glucoside equivalents per gram). Vaccinium angustifolium contributes anthocyanins at higher concentrations than highbush blueberry (~3.9-4.5 mg/g fresh weight basis, primarily delphinidin, cyanidin, petunidin, peonidin, and malvidin glycosides), pterostilbene (~0.03-0.1 mg/g, higher bioavailability than resveratrol due to methyl groups increasing lipophilicity), chlorogenic acid (~1-3 mg/g), and hydroxycinnamic acids. Macronutrient contribution is negligible at standard supplemental doses (typically 100-500 mg extract/day). Micronutrients include trace manganese (~0.1-0.3 mg per serving equivalent), vitamin C (~2-5 mg per serving from berry fraction, largely process-dependent), and vitamin K (trace, <5 mcg). Fiber content is minimal in extract form versus whole fruit. Bioavailability notes: anthocyanins show limited oral bioavailability (~1-2% absorption), metabolized extensively by colonic microbiota into phenolic acids (protocatechuic acid, vanillic acid) which may account for systemic effects; OPC bioavailability is molecular-weight dependent with monomers and dimers absorbed intact while larger polymers require microbial degradation; pterostilbene bioavailability (~80%) substantially exceeds resveratrol (~20-30%) due to enhanced lipid solubility and reduced first-pass metabolism.

Preparation & Dosage

No clinically studied dosages exist for BerryVin. Comparable cranberry extracts in trials used 400 mg capsules daily, with PAC standardization typically at 36 mg/day. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Vitamin C, quercetin, resveratrol, green tea extract, alpha-lipoic acid

Safety & Interactions

BerryVin is generally considered well-tolerated at typical supplemental doses, with the most commonly reported adverse effects being mild gastrointestinal upset, including nausea and loose stools, particularly on an empty stomach. Grape-derived resveratrol and OPCs possess antiplatelet activity and may potentiate the effects of anticoagulants such as warfarin and antiplatelet drugs like clopidogrel, increasing bleeding risk. Vaccinium-derived anthocyanins may modestly affect CYP3A4 and CYP2C9 enzyme activity, potentially altering plasma levels of drugs metabolized by these pathways. Pregnant and breastfeeding individuals should avoid this blend due to insufficient safety data, and individuals scheduled for surgery should discontinue use at least two weeks prior.